Osilodrostat + Placebo

ApprovedRecruiting
0 watching 0 views this week๐Ÿ”ฅ Hot
82
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
โœ“
Phase 3
5
Approved
Indication / Disease

Hypertension

Conditions

Hypertension, Hypercortisolemia, Cushing Syndrome

Trial Timeline

Aug 1, 2026 โ†’ Jul 1, 2028

About Osilodrostat + Placebo

Osilodrostat + Placebo is a approved stage product being developed by Recordati for Hypertension. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07247162. Target conditions include Hypertension, Hypercortisolemia, Cushing Syndrome.

Hype Score Breakdown

Clinical
30
Activity
20
Company
7
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT07247162ApprovedRecruiting